Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 20, Issue 16, Pages 1468-1480Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026620666200309161444
Keywords
beta-lactam; Hybrid compounds; Anticancer; Drug-resistant; Structure-activity relationship; Cancer cell lines
Categories
Funding
- High-Level Talents Research Fund Project [2019gcky05]
- Education and Teaching reform of Chongqing Institute of Engineering [JY2018205]
Ask authors/readers for more resources
Cancer, accounts for around 10 million deaths annually, is the second leading cause of death globally. The continuous emergency of drug-resistant cancers and the low specificity of anticancer agents are the main challenges in the control and eradication of cancers, so it is imperative to develop novel anticancer agents. Immense efforts have been made in developing new lead compounds and novel chemotherapeutic strategies for the treatment of various forms of cancers in recent years. beta-Lactam derivatives constitute versatile and attractive scaffolds for the drug discovery since these kinds of com- pounds possess a variety of pharmacological properties, and some of them exhibited promising potency against both drug-sensitive and drug-resistant cancer cell lines. Thus, beta-lactam moiety is a useful template for the development of novel anticancer agents. This review will provide an overview of beta-lactam derivatives with the potential therapeutic application for the treatment of cancers covering articles published between 2000 and 2020. The mechanisms of action, the critical aspects of design and structure-activity relationships are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available